vaccines

News

Merck's challenge to Pfizer's Prevnar grows

Pfizer's longstanding dominance of the pneumococcal vaccines category could be threatened by Merck & Co, which has just reported new data on its V116 shot in older adu

R&D

Disease X is coming. Are we ready?

Every great disaster movie begins with a scientist being ignored.

News

Novavax secures full EU approval for COVID-19 vaccine Nuvaxo...

In the first of a double dose of wins for US biotech Novavax, the company has been granted full marketing authorisation (MA) by the

News

Sanofi sets out plan to lead the RSV vaccine market

Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a

News

CDC panel backs use of GSK, Pfizer’s RSV shots this year

Adults aged 60 and over in the US will be eligible for vaccinations with respiratory syncytial virus (RSV) vaccines from GSK or Pfizer later this year, if the Centers for

R&D